- Join Clinical Trials for Benign Prostate Hyperplasia

All Categories Medical Conditions » Urinary/Reproductive Disease » Benign Prostate (BPH)

11C Acetate Imaging Post Prostatectomy

Condition: Prostate Cancer
Intervention: Other: 11C Acetate Imaging
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib on Bone Metastases in Patients With Castrate Resistant Prostate Cancer

Conditions: Bone Metastases; Castrate-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: cabozantinib; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: University of Chicago; University of Chicago; NorthShore University Health System
Recruiting - verified May 2012
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer Metastatic
Intervention: Drug: Osteodex
Sponsors: DexTech Medical AB; DexTech Medical AB
Recruiting - verified May 2012
Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Mitoxantrone; Drug: Prednisone; Drug: Pegfilgrastim
Sponsors: University of California, San Francisco; Andrea Harzstark; Sanofi-Aventis
Not yet recruiting - verified May 2012
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Placebo and prednisone; Drug: Abiraterone acetate and prednisone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury

Condition: Urinary Tract Infection
Intervention: Other: sonographic assessment of residual urine, urine culture
Sponsors: Swiss Paraplegic Centre Nottwil; Swiss Paraplegic Centre Nottwil
Recruiting - verified May 2012
Radiotherapy vs Observation for CRPC

Condition: Hormone Refractory Prostate Cancer
Intervention:
Sponsors: Zhengzhou University; Zhengzhou University; The First Affiliated Hospital of Zhengzhou University; the cancer hospital of Zhengzhou University; the fifth affiliated hospital of Zhengzhou University; People's hospital of Zhengzhou University; Zhengzhou central hospital affiliated to Zhengzhou University; Zhengzhou people's hospial; Xinyang central hospital; Zhoukou central hospital; the second people's hospital of kaifeng
Recruiting - verified May 2012
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia and Lower Urinary Track Symptoms (BPH)

Conditions: Benign Prostatic Hyperplasia; Lower Urinary Track Symptoms
Interventions: Drug: onaBoNT-A + placebo; Drug: Tamsulosin + placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System

Condition: Prostate Cancer
Intervention:
Sponsors: U.S. Army Medical Research Acquisition Activity; Dusten Macdonald, MD; The Geneva Foundation
Recruiting - verified May 2012
External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate

Condition: Prostate Cancer
Intervention:
Sponsors: U.S. Army Medical Research Acquisition Activity; Dusten Macdonald; The Geneva Foundation
Recruiting - verified April 2012
COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Other: Blood analysis by EPISPOT and Cellsearch
Sponsors: University Hospital, Montpellier; University Hospital, Montpellier; National Cancer Institute, France; Direction Générale de l'Offre de Soins; Roche Pharma AG
Recruiting - verified May 2012
Cabozantinib in Advanced Solid Malignancies

Conditions: Lung Cancer; Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2012
The Effect of Endurance Training in Patients With Prostate Cancer

Conditions: Prostate Cancer; Insulin Sensitivity; Body Composition, Beneficial
Interventions: Behavioral: endurance training; Behavioral: control group, no behavioral modification
Sponsors: Rigshospitalet, Denmark; Inge Holm; Herlev Hospital
Recruiting - verified April 2012
Acceptance-Based Treatment for Prostate Cancer Distress

Condition: Early Stage Prostate Cancer
Intervention: Behavioral: Acceptance and Commitment Therapy
Sponsors: Veterans Medical Research Foundation; Veterans Medical Research Foundation; Alliant International University; University of California, San Diego
Recruiting - verified April 2012
Saw Palmetto: Symptom Management for Men During Radiation Therapy

Condition: Prostate Cancer
Intervention: Drug: Saw Palmetto
Sponsors: Michigan State University; Michigan State University
Recruiting - verified April 2012
Prostate Advances in Comparative Evidence

Condition: Prostate Cancer
Intervention: Other: CyberKnife prostate SBRT delivered by the CyberKnife in 36.25Gy in 5 fractions or 38Gy in 4 fractions
Sponsors: Accuray Incorporated; Accuray Incorporated; Royal Marsden NHS Foundation Trust, London, UK; Mount Vernon Cancer Center, East & North Herts NHS Trust,Northwood,Middlesex, UK; Centre Oscar Lambret, Lille, France; Charite University, Berlin, Germany; Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; The Institute of Cancer Research, Sutton, Surrey, UK
Recruiting - verified May 2012
Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: focal salvage HDR prostate brachytherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Not yet recruiting - verified April 2012
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Conditions: Advanced Solid Tumor; Lymphoma
Intervention: Drug: DS-3078a
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2012
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer

Condition: Prostate Neoplasms
Intervention: Radiation: "TrueBeam" stereotactic body radiosurgery
Sponsors: Main Line Health; Albert DeNittis
Recruiting - verified April 2012
Intraoperative Monitoring of the Pelvic Autonomic Nerves

Condition: Rectal Cancer
Interventions: Procedure: TME; Procedure: TME; Procedure: Neuromonitoring
Sponsors: Johannes Gutenberg University Mainz; Johannes Gutenberg University Mainz
Not yet recruiting - verified April 2012
Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary

Condition: Granulosa Cell Tumour of the Ovary
Intervention: Drug: Ketoconazole
Sponsors: Grupo Español de Tumores Huérfanos e Infrecuentes; Grupo Español de Tumores Huérfanos e Infrecuentes
Not yet recruiting - verified April 2012
Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery

Condition: Prostate Cancer
Intervention:
Sponsors: University Hospital, Ghent; University Hospital, Ghent
Not yet recruiting - verified April 2012
Medico-economic Comparison of Robot-assisted Radical Prostatectomy Versus Radical Prostatectomy Via Laparotomy

Condition: Prostatic Neoplasms
Intervention:
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified March 2012
Abiraterone Acetate With or Without Veliparib in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: veliparib
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Not yet recruiting - verified April 2012
XL-184+Abiraterone in Post-Chemo CRPC

Condition: Prostate Cancer
Interventions: Drug: Cabozantinib; Drug: Abiraterone
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified April 2012
Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: CABAZITAXEL (XRP6258); Drug: DOCETAXEL (XRP6976)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Not yet recruiting - verified April 2012
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia and Lower Urinary Track Symptoms

Conditions: Nocturia; Benign Prostatic Hyperplasia; Incontinence
Interventions: Drug: onaBoNT-A + placebo; Drug: Tamsulosin + placebo
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Department of Veterans Affairs
Not yet recruiting - verified May 2012
The Use of Thermal Suits as Preventing Hypothermia During Surgery

Condition: Prostate Cancer
Interventions: Device: T-Balance; Other: Control
Sponsors: Tampere University Hospital; Tampere University Hospital
Not yet recruiting - verified March 2012
Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort

Conditions: Prostate Cancer; Robotic Prostatectomy; Foley Catheter Discomfort
Interventions: Drug: Bupivacaine; Drug: Saline
Sponsors: Columbia University; Columbia University
Recruiting - verified March 2012
Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology

Condition: Non Small Cell Lung Cancer
Intervention:
Sponsors: National University Hospital, Singapore; National University Hospital, Singapore
Not yet recruiting - verified April 2012
Prostate Hypoxia FAZA

Condition: Prostate Cancer
Intervention: Other: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified April 2012
Studying Repeated Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in Patients Diagnosed With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: motexafin gadolinium
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Body Mind Training Project

Condition: Cancer Related Fatigue
Interventions: Behavioral: Qigong; Behavioral: Non-aerobic stretching
Sponsors: University of Utah; University of Utah
Recruiting - verified March 2012
Evaluation of Psycho-oncological Intervention in Prostate Cancer Patients on Androgen-deprivation Therapy and Their Partners

Condition: Prostate Cancer
Intervention: Other: Psychological counseling
Sponsors: Ipsen; Ipsen
Not yet recruiting - verified April 2012
Study of Metformin With Simvastatin for Men With Prostate Carcinoma

Condition: Prostate Carcinoma
Interventions: Drug: Metformin; Drug: Simvastatin
Sponsors: Baylor College of Medicine; Nicholas Mitsiades
Recruiting - verified March 2012
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

Condition: Prostate Cancer
Intervention:
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012
Phase II Study of Sipuleucel-T and 1-MT for Patients With Refractory Metastatic Prostate Cancer

Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Biological: 1-MT; Biological: Sipuleucel-T; Other: Placebo
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified April 2012
PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors

Condition: Bladder Cancer
Interventions: Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors; Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Sponsors: Emory University; Emory University; Olympus
Not yet recruiting - verified March 2012
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Procedure: Surveillance; Procedure: Salvage treatment
Sponsors: University Hospital, Ghent; University Hospital, Ghent
Not yet recruiting - verified March 2012
Prospective Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy

Condition: Prostate Cancer
Interventions: Procedure: Limited pelvic Lymphadenectomy; Procedure: Extended pelvic Lymphadenectomy
Sponsors: Association of Urogenital Oncology (AUO); Association of Urogenital Oncology (AUO)
Recruiting - verified March 2012
AMG 386 and Abiraterone for Advanced Prostate Cancer

Conditions: Prostatic Neoplams; Prostate Cancer; Neoplasm, Prostate; Neoplasm,Prostatic
Interventions: Drug: AMG 386; Drug: Abiraterone; Drug: Prednisone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study

Condition: Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified March 2012
Curative Image Guided Radiotherapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiotherapy daily verification reduced safety margins; Radiation: radiotherapy weekly verification standard safety margins
Sponsors: St. Olavs Hospital; St. Olavs Hospital; Norwegian University of Science and Technology; Alesund Hospital
Not yet recruiting - verified March 2012
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Orteronel+Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Not yet recruiting - verified April 2012
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Condition: Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Intervention: Drug: Everolimus (RAD001)
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified March 2012
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: orteronel; Drug: triptorelin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
A Prospective Study to Evaluate MRI Guided Biopsy Compared With Transrectal Ultrasound Guided Biopsy of the Prostate in Men With Increased PSA Values

Condition: Prostate Cancer
Intervention: Device: MRI guided prostate biopsy and TRUS guided biopsy
Sponsors: Heinrich-Heine University, Duesseldorf; Heinrich-Heine University, Duesseldorf
Recruiting - verified March 2012
Safety, Biodistribution, and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Condition: Prostatic Neoplasms
Interventions: Drug: BAY88-8223 (Radium-223 chloride); Drug: BAY88-8223 (Radium-223 chloride)
Sponsors: Bayer; Bayer
Recruiting - verified April 2012
The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: Transperineal Ultrasound
Sponsors: Fletcher Allen Health Care; H. James Wallace, MD; Internal Funding, Elekta Ltd.
Recruiting - verified February 2012
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Condition: Prostate Cancer
Interventions: Drug: TAP-144-SR(6M); Drug: TAP-144-SR(3M)
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified April 2012
Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: MDV3100 + Leuprolide + Dutasteride
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Not yet recruiting - verified March 2012
The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function

Condition: Prostate Cancer
Interventions: Drug: epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose; Drug: no epidural drug administered
Sponsors: Yonsei University; Yonsei University
Recruiting - verified March 2012
Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Conditions: Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Drug: degarelix injection; Drug: degarelix injection
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Ferring Pharmaceuticals
Recruiting - verified April 2012
A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer

Condition: Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: weekly cabazitaxel
Sponsors: Karolinska University Hospital; Jeffrey Yachnin M.D., PhD.; Sanofi-Aventis
Not yet recruiting - verified March 2012
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Condition: Prostatic Neoplasm
Intervention: Radiation: radiation therapy
Sponsors: Sharp Memorial Hospital; Sharp Memorial Hospital
Recruiting - verified March 2012
MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer

Condition: Prostate Cancer
Interventions: Procedure: Core Needle TRUS Needle biopsy (Transrectal ultrasound); Procedure: Core Needle MRI/US image fusion guided needle biopsy
Sponsors: Philips Healthcare; Philips Healthcare
Not yet recruiting - verified May 2012
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: 89Zr-DFO-huJ591
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Broad Institute of MIT and Dana-Farber Cancer Institute of Harvard
Recruiting - verified February 2012
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

Conditions: Solid Malignancies; Metastatic Castrate-resistant Prostate Cancer
Intervention: Drug: axitinib
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Pfizer
Recruiting - verified March 2012
SpaceOAR System Pivotal Study

Condition: Prostate Cancer
Intervention: Device: SpaceOAR System
Sponsors: Augmenix, Inc.; Augmenix, Inc.
Recruiting - verified March 2012
Prostate Cancer Prevention Trial With Quercetin and Genistein

Condition: Primary Prevention of Prostate Cancer
Interventions: Dietary Supplement: Quercetin supplement; Dietary Supplement: Genistein supplement; Dietary Supplement: Placebo
Sponsors: University of Hohenheim; University of Hohenheim; Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany; University Hospital Tübingen, Department of Urology, Tübingen; Provision of study products: Quercegen Pharmaceuticals LLC
Recruiting - verified May 2012
Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified May 2012
Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence

Conditions: Urinary Incontinence; Radical Prostatectomy
Intervention: Device: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)
Sponsors: Copenhagen University Hospital at Herlev; Copenhagen University Hospital at Herlev; Rigshospitalet, Denmark
Not yet recruiting - verified February 2012
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

Conditions: Castration-resistant Prostate Cancer; Stage IV Prostate Cancer
Intervention: Drug: abiraterone acetate
Sponsors: University of Chicago; University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2012
Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: Orion Corporation, Orion Pharma; Orion Corporation, Orion Pharma
Recruiting - verified April 2012
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

Conditions: Breast Cancer; Cancer Survivor; Colorectal Cancer; Lung Cancer; Prostate Cancer; Tobacco Use Disorder
Interventions: Drug: memantine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149)

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Finasteride (MK-906); Drug: Tamsulosin; Other: Placebo
Sponsors: Merck; Merck
Not yet recruiting - verified March 2012
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: linsitinib; Genetic: RNA analysis; Other: circulating tumor cell analysis; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry
Sponsors: National Cancer Institute (NCI); Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Condition: Hot Flashes in Men With Prostate Cancer Receiving Androgen Ablation Therapy
Interventions: Drug: Gabapentin; Drug: Venlafaxine
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012
BPH-6: Comparison of the UroLift System to Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia
Interventions: Device: UroLift(R) System; Procedure: TURP
Sponsors: NeoTract, Inc.; NeoTract, Inc.
Recruiting - verified May 2012
Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: atorvastatin calcium; Drug: placebo
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified March 2012
Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: MDV3100
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified March 2012
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Condition: Prostate Cancer
Interventions: Drug: Androgen Ablation; Drug: Cabazitaxel; Drug: Salvage Therapy; Drug: Neoadjuvant Treatment - Hormonal Therapy; Drug: Neoadjuvant Treatment - Cabazitaxel
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Sanofi-Aventis
Recruiting - verified May 2012
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Ipilimumab and GM-CSF
Sponsors: University of California, San Francisco; University of California, San Francisco; Bristol-Myers Squibb; Genzyme
Not yet recruiting - verified February 2012
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Condition: Melanoma
Intervention: Other: Blood Draw
Sponsors: Comprehensive Cancer Centers of Nevada; Wolfram Samlowski; TrueCells, LLC; Comprehensive Cancer Centers of Nevada; The Scripps Research Institute; University of Pittsburgh
Recruiting - verified February 2012
C11-Acetate PET/CT Imaging in Prostate Adenocarcinoma, Study of Impact in Initial Treatment and in Treatment Monitoring

Conditions: Prostate Cancer; Prostate Adenocarcinoma
Intervention: Drug: C11-Sodium Acetate
Sponsors: Arizona Molecular Imaging Center; Arizona Molecular Imaging Center
Recruiting - verified April 2012
Early Rehabilitation of Cancer Patients

Conditions: Breast Cancer; Colorectal Cancer; Lymphoma; Prostate Cancer; Testicle Cancer
Intervention: Other: Stressmanagement
Sponsors: Haukeland University Hospital; Haukeland University Hospital; University of Bergen; Uppsala University; University of Agder
Recruiting - verified January 2012
QUAPELLA (QUAlity of Prostate Enucleation by LUMENIS - Laser)

Condition: Benign Prostatic Hyperplasia
Intervention: Procedure: Holmium Laser Enucleation of the Prostate (HoLEP)
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified March 2012
Tivantinib in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: tivantinib; Other: placebo
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

Conditions: Prostate Cancer; Benign Prostatic Hyperplasia; Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Intervention: Drug: BOTOX
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified January 2012
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
MR-guided Focused Ultrasound Treatment of Prostate Cancer: Focal Therapy for Locally Non-Advanced Disease

Condition: Prostate Cancer
Intervention: Device: ExAblate 2100; InSightec
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Recruiting - verified January 2012
Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising Prostate Specific Antigen (PSA)

Condition: Prostate Cancer
Intervention: Drug: Acai Juice Product
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified January 2012
A Study That Provides Long-term Access and Examines Long-term Exposure to Abiraterone Acetate

Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified January 2012
Radiation and Androgen Ablation for Prostate Cancer

Condition: Adenocarcinoma of the Prostate
Interventions: Radiation: Radiation Therapy; Drug: Androgen Suppression Therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012
Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 chloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified April 2012
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: tasquinimod; Drug: tasquinimod 0.25 mg; 0.5 mg; Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Sponsors: Duke University; Duke University
Recruiting - verified January 2012
Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Condition: Hormone Refractory Prostate Cancer
Intervention: Drug: Cabazitaxel 10 mg/m2
Sponsors: Spanish Oncology Genito-Urinary Group; Spanish Oncology Genito-Urinary Group
Not yet recruiting - verified January 2012
Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified January 2012
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified April 2012
Pharmacodynamic Study of Abiraterone in the Treatment of Advanced Prostate Cancer

Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma; Hormone Refractory Prostate Cancer; Stage IV Prostate Carcinoma
Interventions: Drug: Abiraterone acetate plus prednisone; Drug: Abiraterone acetate plus prednisone; Drug: Abiraterone acetate plus prednisone
Sponsors: University of Washington; University of Washington; Janssen, LP
Not yet recruiting - verified January 2012
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel XRP6258; Drug: Abiraterone acetate
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Prednisone; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Not yet recruiting - verified January 2012
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011
Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: performance of PET/CT and whole-body MRI
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified December 2011
Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study

Condition: Particle Therapy
Intervention:
Sponsors: University Hospital Heidelberg; University Hospital Heidelberg
Recruiting - verified February 2012
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Intervention: Biological: Ipilimumab
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Condition: Prostate Cancer
Interventions: Dietary Supplement: Se-methyl-seleno-L-cysteine; Dietary Supplement: selenomethionine; Other: placebo
Sponsors: National Cancer Institute (NCI); Robert H. Lurie Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

Condition: Cervical Cancer
Intervention:
Sponsors: Far Eastern Memorial Hospital; Far Eastern Memorial Hospital
Recruiting - verified April 2012
Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia (BPH)
Interventions: Device: Greenlight XPS Laser; Device: BiVAP Saline Vaporization of the prostate
Sponsors: Brooklyn Urology Research Group; Brooklyn Urology Research Group; American Medical Systems; Richard Wolf Medical Instruments Corporation (RWMIC)
Recruiting - verified February 2012
EMBRACE1: Prostate Biorepository

Condition: Prostate Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified January 2012
Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer

Conditions: Solid Tumors; Prostate Cancer
Intervention: Drug: ADI-PEG 20
Sponsors: Polaris Group; Polaris Group
Recruiting - verified December 2011
Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011
A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia

Condition: Prostatic Hyperplasia
Interventions: Drug: Dutasteride (0.5mg, fasted state); Drug: Dutasteride (0.5mg, fed state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state); Drug: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state); Drug: Harnal-D Tablets with water (fasted state); Drug: Harnal-D Tablets with water (fed state); Drug: Harnal-D tablets without water (fasted state)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Condition: Cancer
Intervention: Drug: I-131-CLR1404
Sponsors: Novelos Therapeutics; Novelos Therapeutics
Recruiting - verified December 2011
Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate

Condition: Prostate Cancer
Intervention: Radiation: CyberKnife Boost
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified December 2011
Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

Condition: Prostate Cancer
Interventions: Radiation: Proton Radiation; Drug: Androgen Suppression Therapy
Sponsors: Proton Collaborative Group; Proton Collaborative Group
Recruiting - verified January 2012
Imaging for Significant Prostate Cancer Risk Evaluation

Condition: Prostate Cancer
Interventions: Procedure: Prostate HistoScanning; Procedure: Multi-parametric MRI; Procedure: Transperineal prostate mapping biopsy; Procedure: Image guided biopsies
Sponsors: University College London Hospitals; University College London Hospitals; Advanced Medical Diagnostics s.a.
Recruiting - verified December 2011
Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Conditions: Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T; Drug: abiraterone acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: GEMOX
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified December 2011
Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vaporization of Prostate(PVP)

Condition: Benign Prostate Hyperplasia
Interventions: Procedure: HOLEP (Holmium Laser Enucleation of The Prostate); Procedure: PVP-XPS (Photoselective Vaporization of the Prostate)
Sponsors: Royal Victoria Hospital, Canada; Royal Victoria Hospital, Canada; McGill University
Recruiting - verified January 2012
Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Condition: Prostate Cancer
Intervention: Drug: 99mTc-MIP-1404
Sponsors: Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified April 2012
The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer

Condition: Castration-resistant Prostate Cancer
Interventions: Drug: ADT; Drug: No ADT
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified December 2011
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients

Condition: High-risk Prostate Cancer
Interventions: Radiation: Standard Radiation Treatment; Radiation: Hypofractionated radiation treatment
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified May 2012
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Condition: Prostate Cancer
Interventions: Drug: GDC-0068; Drug: GDC-0980; Drug: placebo; Drug: abiraterone; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

Condition: Prostate Cancer
Intervention:
Sponsors: University Urological Associates Inc.; University Urological Associates Inc.
Not yet recruiting - verified November 2011
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening

Condition: Prostate Cancer
Intervention: Other: PROCASE Decision-Aid
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Urine Metabolomics and Colorectal Cancer Screening

Conditions: Colorectal Cancer; Colorectal Polyps
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011
Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery

Condition: Prostate Cancer
Interventions: Procedure: ultrasound imaging; Procedure: robot-assisted laparoscopic surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: kanglaite gelcap; Drug: Kanglaite gelcap
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified November 2011
Sodium Flouride (NaF) Positron Emission Tomograpy/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Docetaxel-Based Chemo or AR-directed Therapy

Condition: Prostate Cancer
Intervention: Procedure: Sodium Flouride (NaF) Positron Emission Tomograpy/Computed Tomography (PET/CT) imaging
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified January 2012
Second-line Chemotherapy in Castration Resistant Prostate Cancer

Condition: Metastatic Prostate Cancer
Intervention: Drug: cabacitaxel
Sponsors: Tampere University Hospital; Tampere University Hospital; Helsinki University Central Hospital; Turku University Hospital; Kuopio University Hospital; Seinajoki Central Hospital
Recruiting - verified March 2012
A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy

Condition: Prostate Cancer
Intervention: Device: Navigo system
Sponsors: UC Care, Ltd.; UC Care, Ltd.
Recruiting - verified November 2011
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors or Prostate or Kidney Cancer

Conditions: Kidney Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Drug: hydroxychloroquine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer

Condition: Prostate Adenocarcinoma
Intervention: Other: Polymer based fiducial placement
Sponsors: ProCure Proton Therapy Center; John Chang, MD
Recruiting - verified December 2011
Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: SonoVue
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified November 2011
Sipuleucel-T Manufacturing Demonstration Study

Conditions: Cancer of Prostate; Cancer of the Prostate; Neoplasms, Prostate; Neoplasms, Prostatic; Prostate Cancer; Prostate Neoplasms; Prostatic Cancer
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Not yet recruiting - verified April 2012
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction

Conditions: Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Cystitis, Interstitial
Intervention:
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne
Recruiting - verified November 2011
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Condition: Castration Resistant Prostate Cancer
Intervention: Drug: NRX 194204
Sponsors: Io Therapeutics; Io Therapeutics
Recruiting - verified February 2012
Oral Colchicine in Men With Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Colchicine
Sponsors: Penn State University; Penn State University
Not yet recruiting - verified May 2012
Firmagon (Degarelix) Intermittent Therapy

Condition: Prostate Cancer Recurrent
Intervention: Drug: degarelix
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; Ferring Inc.
Not yet recruiting - verified January 2012
L-BLP25 (Stimuvax) in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Radiation; Drug: Androgen Deprivation Therapy (ADT); Other: Standard of care; Drug: L-BLP25
Sponsors: EMD Serono; EMD Serono
Recruiting - verified December 2011
Pre-Prostatectomy Lovastatin on Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Lovastatin
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Conditions: Diarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: cabazitaxel; Drug: prednisone; Drug: octreotide pamoate; Other: questionnaire administration; Drug: octreotide acetate
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Sanofi-Aventis
Not yet recruiting - verified May 2012
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness

Conditions: Prostatic Neoplasms; Genital Neoplasms, Male; Prostatic Diseases
Intervention:
Sponsors: Oslo University Hospital; Oslo University Hospital; Radboud University
Recruiting - verified October 2011
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: docetaxel; Drug: pasireotide; Drug: prednisone
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Conditions: Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified November 2011
Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy

Conditions: Prostate Cancer; Immune Profile; Circulating Cancer Cells; Clinical Corelation
Interventions: Procedure: Prostate cryotherapy; Procedure: Radical prostatectomy; Procedure: Radiation
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified December 2011
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency

Condition: Cancer
Intervention: Drug: GSK2636771
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.

Conditions: Prostate Cancer; Erectile Dysfunction
Interventions: Procedure: Application of a hemostatic gelatin-thrombin matrix; Procedure: Use of mono- and bipolar electrocautery and surgical clips
Sponsors: Johann Wolfgang Goethe University Hospitals; Johann Wolfgang Goethe University Hospitals
Recruiting - verified October 2011
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiation
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified January 2012
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Degarelix
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Not yet recruiting - verified November 2011
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men

Conditions: Prostate Cancer; Cancer
Interventions: Behavioral: Post-Test Questionnaire; Behavioral: Interviews; Behavioral: Focus Groups
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Not yet recruiting - verified April 2012
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Biological: mRNA transfected dendritic cell; Drug: Docetaxel
Sponsors: Herlev Hospital; Inge Marie Svane
Recruiting - verified October 2011
Study of Itraconazole in Castration Resistant Prostate Cancer (CRPC) Post Docetaxel Chemotherapy

Conditions: Prostate Cancer; Metastatic Disease
Intervention: Drug: Itraconazole
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate

Condition: Prostate Cancer
Interventions: Radiation: hypofractionation; Radiation: conventional
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital
Not yet recruiting - verified September 2011
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Expressed Prostatic Secretion and Post Massage Urine Biomarkers in Predicting Biopsy Results in Patients Undergoing Prostate Biopsy

Conditions: Conditions Influencing Health Status; Healthy; Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: transrectal prostate biopsy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Collection of Blood From Cancer Patients for Genetic Analysis

Conditions: Prostate Cancer; Breast Cancer; Lung Cancer; Ovarian Cancer; Lymphoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Stereotactic Body Radiation; Drug: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified September 2011
MRI and Ultrasound Soft Image Fusion Compared to Gold Standard Prostate Biopsies

Condition: Prostate Cancer
Interventions: Procedure: Koelis; Procedure: Gold standard biopsy
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified May 2012
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Condition: Benign Prostatic Hyperplasia
Intervention: Drug: NX-1207
Sponsors: Nymox Corporation; Nymox Corporation
Recruiting - verified November 2011
Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: AdV-tk + valacyclovir; Biological: Placebo + valacyclovir
Sponsors: Advantagene, Inc.; Advantagene, Inc.
Recruiting - verified May 2012
A Study to Measure Needle Bending and Changes in Prostate Shape During a Prostate Seed Implant

Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia

Conditions: Bladder Neck Obstruction; Benign Prostate Hyperplasia
Intervention: Device: Insertion of Temporary Implantable Nitinol Device (TIND)
Sponsors: Meditate; Meditate
Recruiting - verified September 2011
Radiation Therapy in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexual Dysfunction
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of Metformin in Patients With Prostate Cancer Undergoing Prostate Surgery

Condition: Prostate Cancer
Interventions: Drug: metformin; Drug: Placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); University of Arizona
Not yet recruiting - verified October 2011
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer

Condition: Prostatic Neoplasms
Intervention:
Sponsors: Copenhagen University Hospital at Herlev; Copenhagen University Hospital at Herlev
Recruiting - verified February 2012
Doxazosin an a1 Antagonist for Alcohol Dependence

Conditions: Alcohol Dependence; Anxiety
Interventions: Drug: Doxazosin; Drug: Placebo
Sponsors: Brown University; Brown University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified September 2011
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC
Interventions: Drug: Cabazitaxel-XRP6258; Drug: Cabazitaxel-XRP6258
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Sanofi-Aventis
Recruiting - verified April 2012
Evaluating Personalized Effect of an Individualized Intervention

Condition: Colorectal Cancer
Intervention: Procedure: Energy healing
Sponsors: University of Southern Denmark; University of Southern Denmark; University of Aarhus; The Ministry of Science, Technology and Innovation, Denmark
Recruiting - verified February 2012
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Condition: Prostate Cancer
Intervention: Drug: ODM-201
Sponsors: Orion Corporation, Orion Pharma; Orion Corporation, Orion Pharma
Recruiting - verified March 2012
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: APC-100
Sponsors: Adamis Pharmaceuticals Corporation; Adamis Pharmaceuticals Corporation
Recruiting - verified September 2011
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
Sponsors: University of Michigan Cancer Center; David C Smith; Exelixis
Recruiting - verified March 2012
Randomized RT +/- Lapatinib for Prostate Cancer Patients Receiving Radiation Therapy for Bone Metastases

Condition: Prostate Cancer
Interventions: Drug: Lapatinib; Radiation: Radiation therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified January 2012
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Conditions: Febrile Neutropenia; Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Prostate Cancer; Multiple Myeloma; Bladder Cancer; B-cell Lymphoma
Intervention:
Sponsors: Sandoz; Sandoz
Recruiting - verified October 2011
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Abiraterone acetate and prednisone; low-fat diet; Drug: Abiraterone acetate and prednisone; high-fat diet
Sponsors: Janssen-Ortho Inc., Canada; Janssen-Ortho Inc., Canada
Recruiting - verified May 2012
Pilot Study on Focal Prostate Radio-Frequency Ablation

Condition: Prostate Cancer
Intervention: Device: Radio-Frequency Ablation (RFA) ENCAGE™
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Trod Medical, US,LLC
Recruiting - verified May 2012
Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time

Condition: Prostatic Neoplasms
Interventions: Radiation: Image-guided radiotherapy; Radiation: Image-guided radiotherapy
Sponsors: CancerCare Manitoba; CancerCare Manitoba; Sunnybrook Health Sciences Centre
Recruiting - verified February 2012
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Anti-Androgen Therapy: Bicalutamide; Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Sanofi-Aventis
Recruiting - verified January 2012
DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study

Condition: Prostate Cancer
Intervention: Radiation: Radiation: pelvic lymph nodes with boost to prostate
Sponsors: University of Aarhus; University of Aarhus; Rigshospitalet, Denmark; Herlev Hospital; Odense University Hospital; Vejle Hospital; Aalborg Hospital; Danish Center for Interventional Research in Radiation Oncology (CIRRO)
Recruiting - verified March 2012
PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)

Condition: Prostate Cancer
Intervention:
Sponsors: Toowoomba Regional Cancer Research Centre; Toowoomba Regional Cancer Research Centre; Abbott
Recruiting - verified June 2011
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
Sponsors: Progenics Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
Sponsors: Progenics Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011
Spectro-IRM and Evaluation Response to Prostatic Radiotherapy

Condition: Prostate Cancer
Intervention: Other: MR-Spectroscopy
Sponsors: Centre Georges Francois Leclerc; Centre Georges Francois Leclerc
Recruiting - verified August 2011
Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.

Conditions: Radiation Enteritis; Radiation Proctitis
Interventions: Dietary Supplement: FructoOligoSaccharide; Dietary Supplement: Maltodextrin
Sponsors: University College London Hospitals; University College London Hospitals
Recruiting - verified August 2010
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T; Drug: leuprolide acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

Conditions: Prostate Cancer; Prostate Adenocarcinoma
Interventions: Radiation: Standard Salvage Radiation Treatment (SSRT); Radiation: Mapped Tumor Salvage RT (MTSRT); Procedure: DCE-MRI of Pelvis/Prostate; Procedure: Bone Scan; Procedure: Ultrasound Prostate Bed Biopsy; Procedure: Urine Sample Collection; Procedure: Blood Sample Collection; Behavioral: EPIC SF-12 Questionnaire; Behavioral: MAC-PC Questionnaire
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
Multimodal Therapy for Treatment of Fatigue

Condition: Prostate Cancer
Interventions: Other: Placebo; Drug: Methylphenidate; Behavioral: Counseling Sessions; Other: Sham Exercise; Other: Standardized Exercise Intervention Program; Other: Cognitive Behavioral Therapy (CBT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; American Cancer Society
Recruiting - verified April 2012
Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Prostate SBRT with concurrent boost to intraprostatic lesion(s)
Sponsors: Rocky Mountain Cancer Centers; Rocky Mountain Cancer Centers; Dr. Dennis Carter
Recruiting - verified August 2011
A Phase I Trial of MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer

Conditions: Prostate Cancer; Prostate Adenocarcinoma
Interventions: Radiation: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy; Radiation: Standard IMRT; Behavioral: EPIC SF-12 Questionnaire; Behavioral: MAX-PC Questionnaire; Behavioral: IPSS Questionnaire; Procedure: Blood Sample Collection; Procedure: Urine Sample Collection; Procedure: Prostate Biopsy; Procedure: CT Simulation; Procedure: MRI Simulation; Procedure: Fiducial Gold Marker Placement
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial

Conditions: Prostate Cancer; Prostate Adenocarcinoma
Interventions: Radiation: Standard Fractionated Intensity Modulated Radiotherapy (SIMRT); Radiation: Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT); Behavioral: EPIC SF-12 Questionnaire; Behavioral: MAX-PC Questionnaire; Behavioral: IPSS Questionnaire; Procedure: Ultra-Sound Guided Biopsy; Procedure: Prostate Fiducial Marker Placement; Procedure: Blood Sample Collection; Procedure: DCE-MRI; Procedure: CT Simulation; Procedure: MRI Simulation; Procedure: Bone Scan
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy

Condition: Prostate Cancer
Intervention: Radiation: brachytherapy
Sponsors: University Hospital Erlangen; University Hospital Erlangen
Not yet recruiting - verified March 2011
Neoadjuvant Axitinib in Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: ADT Therapy; Drug: Axitinib; Procedure: Prostatectomy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012
Trial of Modifications to Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Procedure: Fascial suturing; Procedure: Lymph node template
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Tamsulosin 0.4mg; Drug: Tamsulosin 0.2mg
Sponsors: Samsung Medical Center; Samsung Medical Center
Not yet recruiting - verified July 2011
The Prostate Immobilization Device Study

Condition: Adenocarcinoma of the Prostate
Intervention: Device: Prostate gland immobilization with rectal balloon
Sponsors: Wheaton Franciscan Healthcare; James Taylor
Recruiting - verified May 2012
EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients

Condition: Adenocarcinoma of the Prostate
Interventions: Biological: EPISPOT detection of the number of circulating cells; Biological: CellSearch detection of the number of circulating, functional, prostate cells
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Recruiting - verified January 2012
A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer

Condition: Rectal Cancer
Interventions: Procedure: robot-assisted surgery; Procedure: Laparoscopic surgery
Sponsors: Kyungpook National University; Kyungpook National University
Recruiting - verified November 2011
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Cohort 4; Drug: Cohort 3; Drug: Cohort 2; Drug: Cohort 1
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Recruiting - verified May 2012
Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Adjuvant Androgen-Deprivation Therapy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified December 2011
Safety Study of MGA271 in Refractory Cancer

Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011
A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)

Conditions: Chronic Abacterial Prostatitis; Chronic Pelvic Pain Syndrome
Interventions: Drug: ASP3652; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified November 2011
End of Life Treatment Preferences

Condition: Advanced Cancers
Intervention: Behavioral: Telephone Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; JSS Medical Research Inc.; CMX Research; CMX Research Inc
Recruiting - verified March 2012
BKM120 in Metastatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Metastatic
Intervention: Drug: BKM120
Sponsors: Duke University; Duke University; Novartis Pharmaceuticals
Recruiting - verified October 2011
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Conditions: Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: axitinib; Procedure: therapeutic conventional surgery; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: DOCETAXEL
Sponsors: Asan Medical Center; Hanjong Ahn
Recruiting - verified February 2012
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate; Drug: Dutasteride; Drug: Prednisone
Sponsors: Dana-Farber Cancer Institute; Mary-Ellen Taplin, MD
Recruiting - verified February 2012
Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy

Condition: Prostate Cancer
Interventions: Device: RapidStrand seeds for use with 18g needle; Device: ThinStrand
Sponsors: Prostate Cancer Foundation of Chicago; Prostate Cancer Foundation of Chicago
Recruiting - verified June 2011
Male Stress Urinary Incontinence and Sexual Health

Condition: Prostate Cancer
Interventions: Device: Artificial urinary sphincter; Device: InVance Sling; Device: AdVance Sling; Device: Virtue Sling; Drug: Contigen
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
MR Image Guided Therapy in Prostate Cancer

Conditions: Prostate Cancer; Prostatic Neoplasms
Intervention: Device: Visualase Thermal Therapy System
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University Hospital Tuebingen; University Hospital Tuebingen
Recruiting - verified March 2011
Hypofractionated Stereotactic Boost in Prostate Cancer

Condition: Cancer
Interventions: Radiation: First part of treatment : Conformal irradiation; Procedure: Fiducials placement; Radiation: Second part : hypofractionated stereotactic boost
Sponsors: Centre Oscar Lambret; Centre Oscar Lambret
Recruiting - verified May 2012
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: Brachytherapy + Decapeptyl® SR 22.5mg Triptorelin; Radiation: Brachytherapy
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas

Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
Sponsors: Centre Georges Francois Leclerc; Centre Georges Francois Leclerc; AstraZeneca
Recruiting - verified January 2012
Pazopanib, Docetaxel, Prednisone Prostate

Condition: Prostate Cancer
Interventions: Drug: Pazopanib; Drug: Docetaxel; Drug: Pazopanib; Drug: Prednisone
Sponsors: Duke University; Duke University; GlaxoSmithKline
Recruiting - verified July 2011
Assessment of New Radiation Oncology Technologies and Treatments

Conditions: Prostate Cancer (Post Prostatectomy); Anal Cancer; Nasopharyngeal Cancer; Intermediate Risk Prostate Cancer
Intervention: Other: Non-Interventional Study
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified June 2011
CYP19A1 Gene and Pharmacogenetics of Response to Testosterone Therapy

Condition: Hypogonadism
Interventions: Drug: Testosterone Cypionate; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study

Condition: Prostate Cancer
Intervention:
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Proton Radiation Therapy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Condition: Prostate Cancer
Intervention:
Sponsors: CMX Research; CMX Research; Ferring Pharmaceuticals
Recruiting - verified February 2012
A Study to Assess Efficacy and Safety With VESIcare® to Improve Urinary Continence in Subjects After Robotic Assisted Radical Prostatectomy

Condition: Urinary Incontinence
Interventions: Drug: solifenacin succinate; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
Improving Continence and Quality of Life in Prostate Cancer Patients

Conditions: Urinary Incontinence; Mood
Intervention: Behavioral: BF+GROUP; BF+PHONE
Sponsors: Case Western Reserve University; Case Western Reserve University; National Institutes of Health (NIH)
Recruiting - verified May 2011
Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy

Conditions: Prostatic Neoplasms; Adenocarcinoma
Interventions: Procedure: Robotic Radical Prostatectomy; Procedure: Open Radical Prostatectomy
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified September 2011
Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

Condition: Prostate Cancer
Intervention: Other: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Colorado, Denver; M.D. Anderson Cancer Center; North Shore Long Island Jewish Health System
Recruiting - verified April 2012
Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences

Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services; Canadian Association of Radiation Oncology; Sanofi-Aventis
Recruiting - verified April 2012
Active Surveillance Magnetic Resonance Imaging Study

Condition: Prostate Cancer
Intervention: Device: MRI assisted TRUS guided biopsy
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; OICR; Eigen
Recruiting - verified March 2012
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques

Condition: Bone Metastases
Intervention: Radiation: BS, SPECT/CT, PET/CT, MRI
Sponsors: Turku University Hospital; Turku University Hospital
Recruiting - verified November 2011
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
Sponsors: Enzon Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc.
Recruiting - verified February 2012
EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012
Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer

Condition: Prostatic Neoplasms
Intervention: Device: magnetic resonance imaging, Siemens
Sponsors: University of Oulu; University of Oulu; Oulu University Hospital
Recruiting - verified April 2012
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Conditions: Castration-resistant Prostate Cancer,; Metastatic Breast Cancer
Intervention: Drug: LFA102
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
An Open Label Prostate Cancer Study in Japanese Patients

Condition: Prostate Cancer
Intervention: Drug: AZD3514
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012
Study of Cabazitaxel Plus Bavituximab as Second-line Chemotherapy for Patients With Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Prostatic Neoplasms
Intervention: Drug: Cabazitaxel plus bavituximab
Sponsors: University of California, Irvine; University of California, Irvine; Peregrine Pharmaceuticals
Recruiting - verified August 2011
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Canada Inc.
Recruiting - verified March 2012
Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian; Fallopian Tube; or Primary Peritoneal Cancer
Intervention: Drug: ABT-767
Sponsors: Abbott; Abbott
Recruiting - verified April 2012
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: pTVG-HP; Biological: rhGM-CSF
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012
Study of Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: Vitamin D and Genistein; Other: Placebo
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Rochester; University of Minnesota - Clinical and Translational Science Institute; Lahey Clinic; Urology San Antonio
Recruiting - verified January 2012
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V/F-TRICOM + GM-CSF; Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified January 2012
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: prednisolone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Dose Response Effects of Exogenous Testosterone on the Prostate

Condition: Healthy
Intervention: Drug: Testosterone 1% gel (or placebo) + acyline (or placebo)
Sponsors: University of Washington; University of Washington; National Institutes of Health (NIH); National Institute on Aging (NIA)
Not yet recruiting - verified June 2011
18-F-Fluoroacetate as PET Imaging Agent

Conditions: Brain Cancer; Breast Cancer; Prostate Cancer
Intervention: Drug: 18F-fluoroacetate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified December 2011
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Condition: Refractory Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Hamburg-Eppendorf; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified January 2012
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Muscadine Plus Grape Skin Extract
Sponsors: Johns Hopkins University; Johns Hopkins University; Howard University; Department of Defense: Prostate Cancer Clinical Trial Consortium
Recruiting - verified March 2011
SOM 230 and Everolimus in Combination for the Treatment of Prostate Cancer

Conditions: Castrate Resistant Prostate Cancer; Chemotherapy Naive Prostate Cancer; Prostate Cancer
Interventions: Drug: Pasireotide; Drug: Combination treatment with SOM230 and Everolimus
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Novartis Pharmaceuticals
Recruiting - verified January 2012
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Condition: Prostate Cancer
Interventions: Drug: Lanreotide, non steroidal anti androgens and LHRH-a; Drug: Non steroidal anti androgens and LHRH-a
Sponsors: Ipsen; Ipsen
Not yet recruiting - verified April 2012
Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery

Conditions: Colorectal Cancer; Pain; Other Complications
Interventions: Drug: Ropivacaine + opioid epidurally; Drug: Morphine
Sponsors: Örebro University, Sweden; Örebro University, Sweden; University Hospital, Linkoeping
Recruiting - verified March 2012
Effectiveness of Open and Robotic Prostatectomy

Condition: Prostate Cancer
Intervention: Other: Questionnaire
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; The Cleveland Clinic; Johns Hopkins University; University of California, San Francisco; University of Michigan; Vanderbilt University; Washington University School of Medicine
Recruiting - verified May 2012
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: ODM-201
Sponsors: Orion Corporation, Orion Pharma; Orion Corporation, Orion Pharma
Recruiting - verified March 2012
Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Following Radical Prostatectomy

Condition: Postoperative Pain
Interventions: Drug: Naropine; Drug: Naropine; Other: Placebo
Sponsors: Rigshospitalet, Denmark; Rigshospitalet, Denmark
Recruiting - verified August 2011
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Conditions: Locally Advanced Malignant Neoplasm; Malignant Solid Tumour
Intervention: Biological: ALT-836 in combination with gemcitabine
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation
Recruiting - verified September 2011
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Condition: Prostate Cancer
Intervention: Drug: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2012
Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors

Conditions: Breast Cancer; Colorectal Cancer; Prostate Cancer
Interventions: Behavioral: Standard Arm (mail/telephone); Behavioral: Internet Arm; Behavioral: Surveys and Questionnaires; Behavioral: Exercise and Diet
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Condition: Prostate Cancer
Interventions: Drug: TOOKAD® Soluble; Other: Active Surveillance
Sponsors: Steba Biotech S.A.; Steba Biotech S.A.
Recruiting - verified February 2012
In Vivo Dosimetry During Prostate Cancer Radiotherapy

Condition: Prostate Disease
Intervention: Device: Plastic Scintillation Detectors
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Condition: Prostate Cancer
Intervention: Drug: Sodium Acetate C11
Sponsors: Arizona Molecular Imaging Center; Arizona Molecular Imaging Center
Recruiting - verified April 2012
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

Condition: GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: combination therapy; Drug: alpha blocker monotherapy; Drug: 5 alpha reductase inhibitor monotherapy
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified December 2011
Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block

Condition: Prostate CA
Interventions: Drug: Dexamethasone; Procedure: TAP block
Sponsors: Steward St. Elizabeth's Medical Center of Boston, Inc.; Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified February 2011
Vitamin D Supplementation and Male Infertility: a Randomized Clinical Trial

Condition: Male Infertility
Interventions: Drug: Cholecalciferol and calcium; Other: Placebo
Sponsors: Rigshospitalet, Denmark; Rigshospitalet, Denmark
Recruiting - verified February 2011
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in Russia

Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; Almedis
Recruiting - verified February 2012
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Ferumoxytol
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Conditions: Metastatic Cancer; Cancer; Solid Tumors
Intervention: Drug: BIND-014
Sponsors: BIND Biosciences; BIND Biosciences
Recruiting - verified June 2011
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified March 2012
MRI in Diagnosing Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Other: study of socioeconomic and demographic variables; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Procedure: multiparametric magnetic resonance imaging; Procedure: quality-of-life assessment; Procedure: transperineal prostate biopsy; Procedure: transrectal prostate biopsy; Procedure: ultrasound-guided prostate biopsy
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Not yet recruiting - verified September 2011
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Condition: Overactive Bladder
Interventions: Drug: Fesoterodine 8mg; Drug: Fesoterodine 4mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

Conditions: Overactive Bladder; Bladder, Overactive; Overactive Urinary Bladder
Interventions: Drug: Fesoterodine 8 mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study

Condition: Bladder Outlet Obstruction
Intervention: Device: Dynamic Urine Vibration "Holter"
Sponsors: Meir Medical Center; Meir Medical Center
Not yet recruiting - verified July 2011
Finasteride Challenge

Condition: Prostate Cancer
Intervention: Drug: Finasteride
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Institutes of Health (NIH)
Recruiting - verified August 2011
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)

Condition: Advanced Cancer
Interventions: Drug: ridaforolimus; Drug: MK-0752; Drug: MK-2206
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

Condition: Prostatic Cancer
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: DSTP3086S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Conditions: Prostate Neoplasms; Prostate Cancer; Castration Resistant Prostate Cancer (CRPC)
Intervention: Drug: MDV3100
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified December 2011
Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer

Conditions: Breast Cancer; Prostate Cancer; Osteopenia; Osteoporosis
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified February 2012
A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy

Condition: Prostatic Hyperplasia
Interventions: Drug: BONT-A intra-prostatic injection; Drug: Optimized medical BPH treatment
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified September 2011
Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

Condition: Prostate Cancer
Interventions: Behavioral: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls; Behavioral: Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); Center for Marital and Sexual Health of South Florida
Recruiting - verified November 2011
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

Condition: Prostate Cancer
Intervention: Radiation: radiation therapy
Sponsors: Swiss Group for Clinical Cancer Research; Swiss Group for Clinical Cancer Research
Recruiting - verified May 2012
Rehabilitation After Radiotherapy for Prostate Cancer

Conditions: Urinary Irritative/Incontinence Problems; Bowel Problems; Sexual Problems; Hormonal Problems; Phycological Problems
Intervention: Behavioral: RePCa A
Sponsors: Odense University Hospital; Odense University Hospital
Recruiting - verified January 2011
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: Hsp90 inhibitor STA-9090; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Genetic: RNA analysis; Other: spectrophotometry; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: gene expression analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
The Association of G9a Protein and Outcome of Patients With Endometrial Cancer

Condition: Outcome of Endometrial Cancer
Intervention: Other: no drug
Sponsors: Far Eastern Memorial Hospital; Far Eastern Memorial Hospital
Recruiting - verified July 2011
Prevalence of Human Papillomavirus in Men Living in the Northern Plains

Condition: Human Papillomavirus Infection
Intervention:
Sponsors: Sanford Health; Sanford Health
Recruiting - verified September 2011
Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation

Condition: Prostate Cancer Prevention
Interventions: Dietary Supplement: sulforaphane glucosinolate capsules; Dietary Supplement: Gelatin capsule containing cellulose and magnesium stearate
Sponsors: Portland VA Medical Center; National Cancer Institute (NCI); Oregon State University; Portland VA Medical Center; OHSU Knight Cancer Institute
Recruiting - verified February 2011
Prohibitin Targeting Peptide 1

Condition: Prostate Cancer
Intervention: Drug: Prohibitin-TP01
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel

Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011
Maximum Androgen Depletion

Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: Sunitinib; Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb; Ortho Biotech, Inc.; Pfizer
Recruiting - verified April 2012
BR55 in Prostate Cancer: an Exploratory Clinical Trial

Condition: Prostate Cancer
Intervention: Drug: BR55
Sponsors: Bracco Diagnostics, Inc; Bracco Diagnostics, Inc; Bracco Imaging SpA
Recruiting - verified April 2012
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Condition: Prostate Cancer Metastatic
Intervention: Drug: CABAZITAXEL
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Bicalutamide With or Without MK2206 in Treating Patients With Previously Treated Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phenelzine Sulfate and Docetaxel for Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Conditions: Adenocarcinoma of the Prostate; Castrate Resistant Prostate Cancer; Recurrent Prostate Cancer
Interventions: Drug: docetaxel; Procedure: prostate biopsy; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Drug: phenelzine sulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: 18F-DCFBC
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified August 2011
CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse

Conditions: Prostate Cancer; Interstitial Radiation; High Dose Rate Brachytherapy; Ultrasound-based Planning Compared to CT-based Planning
Intervention: Radiation: HDR prostate brachytherapy
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Recruiting - verified June 2011
Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Prednisone; Drug: Docetaxel
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012
Study of Hypo-fractionated Proton Radiation for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Proton Radiation; Radiation: Proton Radiation
Sponsors: Proton Collaborative Group; Proton Collaborative Group
Recruiting - verified April 2012
Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients

Condition: Prostate Cancer
Interventions: Drug: Docetaxel every 3 weeks + Prednisone; Drug: Docetaxel weekly+ Prednisone
Sponsors: UNICANCER; UNICANCER
Recruiting - verified February 2012
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

Conditions: Clinical Stage T2b or Less of Prostate Cancer; Prostate Brachytherapy; Transrectal Prostate Ultrasound Treatment Planning
Interventions: Other: An ultrasound-based technique to identify prostate cancer; Other: pre-implant transrectal ultrasound images and planning; Other: ultrasound-based cancer-specific images
Sponsors: Beth Israel Medical Center; Beth Israel Medical Center; Riverside Research Instutute,New York, NY
Recruiting - verified January 2012
Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasibility Study

Condition: Localized Low-Risk Prostate Cancer
Intervention: Device: MRgFUS Treatment
Sponsors: InSightec; InSightec
Recruiting - verified February 2012
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Advanced Prostate Cancer

Condition: Prostate Neoplasms
Intervention: Drug: ASG-5ME
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Seattle Genetics, Inc.
Recruiting - verified March 2012
Multi-Institutional Registry for Prostate Cancer Radiosurgery

Conditions: Prostate Cancer Treated by Radiosurgery Early Risk; Prostate Cancer Treated by Radiosurgery Intermediate Risk
Intervention:
Sponsors: Florida Robotic Radiosurgery Association; Florida Robotic Radiosurgery Association
Recruiting - verified April 2012
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Condition: NY-ESO-1 Positive Solid Tumors or Melanoma
Intervention: Biological: IMF-001
Sponsors: ImmunoFrontier, Inc.; ImmunoFrontier, Inc.
Recruiting - verified January 2012
A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia
Intervention: Device: GreenLight XPS vs. TURP
Sponsors: American Medical Systems; American Medical Systems
Recruiting - verified February 2011
A Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: acupuncture
Sponsors: Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Recruiting - verified September 2011
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: zoledronate therapy
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; Department of Defense
Recruiting - verified November 2011
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified June 2011
Vaccine Therapy in Curative Resected Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Biological: Dendritic cell vaccine
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified May 2012
A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers

Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
High-Intensity Focused Ultrasound in Treating Patients With Localized Prostate Cancer

Conditions: Male Erectile Disorder; Prostate Cancer; Therapy-related Toxicity; Urinary Incontinence
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: multiparametric magnetic resonance imaging; Procedure: quality-of-life assessment; Procedure: transperineal prostate biopsy; Procedure: transrectal prostate biopsy
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified November 2010
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel; Drug: TroVax + Docetaxel
Sponsors: Oxford BioMedica; Oxford BioMedica; MedSource
Recruiting - verified February 2012
Dutasteride in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: dutasteride; Drug: gadolinium-chelate; Other: active surveillance; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: functional magnetic resonance imaging; Procedure: prostate biopsy; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified August 2011
Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients

Condition: Prostate Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012
Neoadjuvant Ipilimumab in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Leuprolide Acetate; Drug: Ipilimumab; Procedure: Radical Prostatectomy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)

Condition: Prostate Cancer
Intervention:
Sponsors: Advanced Medical Diagnostics s.a.; Advanced Medical Diagnostics s.a.
Recruiting - verified March 2012
Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance

Condition: Prostate Cancer
Intervention: Device: Pimonidazol
Sponsors: University of Zurich; University of Zurich
Recruiting - verified November 2011
A Study of PNT2258 in Patients With Advanced Solid Tumors

Conditions: Cancer; Lymphoma; Prostate; Melanoma
Intervention: Drug: PNT2258
Sponsors: Pronai Therapeutics, Inc; Pronai Therapeutics, Inc
Recruiting - verified June 2011
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012
Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Condition: Prostatic Neoplasms
Intervention: Drug: JNJ-212082
Sponsors: Janssen Pharmaceutical K.K.; Janssen Pharmaceutical K.K.
Recruiting - verified May 2012
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Condition: Advanced Cancers
Interventions: Drug: Lenalidomide; Drug: Bevacizumab; Drug: Sorafenib; Drug: Temsirolimus; Drug: Lenalidomide; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: GE-148 (18F)
Sponsors: GE Healthcare; GE Healthcare; National Cancer Institute (NCI)
Recruiting - verified September 2011
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in the Treatment of Patients With Castration-Resistant Prostate Cancer Resistant to Docetaxel

Condition: Prostate Cancer
Intervention: Biological: Cancer Macrobead placement in abdominal cavity
Sponsors: The Rogosin Institute; The Rogosin Institute
Recruiting - verified April 2012
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Conditions: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: vorinostat; Drug: temsirolimus; Other: laboratory biomarker analysis; Procedure: positron emission tomography/computed tomography
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012
High Risk Prostate Cancer Prevention Study

Condition: Prostate Cancer
Intervention: Dietary Supplement: finasteride and Isoflavones
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer

Conditions: Prostate Cancer; Radiotherapy; MRI
Interventions: Radiation: FLAME boost; Radiation: standard arm
Sponsors: UMC Utrecht; UMC Utrecht
Recruiting - verified September 2011
Open Label Prostate Cancer Study

Condition: Prostate Cancer
Intervention: Drug: AZD3514
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Digoxin for Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Digoxin
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012
Study of Blood Samples in Predicting How Patients With Prostate Cancer Will Respond to Treatment With Docetaxel

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: docetaxel; Genetic: RNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: circulating tumor cell analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified January 2011
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Prostate Cancer; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Drug: doxorubicin-GnRH agonist conjugate AEZS-108
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; AEterna Zentaris
Recruiting - verified May 2012
A Study in Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers

Conditions: Prostate Cancer; Prostate Adenocarcinoma
Intervention: Procedure: Surgery combined with IMRT-IGRT
Sponsors: Rennes University Hospital; Rennes University Hospital; Center Eugene Marquis
Recruiting - verified February 2012
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: fowlpox-PSA-TRICOM vaccine; Biological: vaccinia-PSA-TRICOM vaccine; Drug: docetaxel; Drug: prednisone
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Condition: Prostate Cancer
Interventions: Biological: engineered autologous T cells; Drug: cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Department of Defense
Recruiting - verified March 2012
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Condition: Prostate Cancer
Intervention: Other: MRI examination
Sponsors: Radboud University; Radboud University; Siemens AG; Mount Vernon Hospital; Multi-Imagem and CDPI, Rio de Janeiro, Brasil; Norwegian University of Science and Technology; University of California, Los Angeles; University Hospital, Ghent; Johns Hopkins University; German Cancer Research Center; Medical University of Vienna; University Health Network, Toronto; University of Heidelberg
Recruiting - verified July 2011
Genistein in Treating Patients With Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer
Interventions: Dietary Supplement: genistein; Other: placebo; Procedure: therapeutic conventional surgery
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified May 2012
Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.

Condition: 2 Years PSA Recurrence Rate
Intervention:
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
OGX-427 in Castration Resistant Prostate Cancer Patients

Condition: Castration Resistant Prostate Cancer
Interventions: Drug: OGX-427 and Prednisone; Drug: Prednisone
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; OncoGenex Technologies, Inc.
Recruiting - verified December 2011
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: ZD4054
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; AstraZeneca
Recruiting - verified November 2011
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Intervention: Radiation: intensity modulated external beam radiation therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified January 2012
Influence of Selenium on Biomarkers of Prostate Cancer Risk

Condition: Prostate Cancer
Interventions: Other: Placebo; Drug: SM; Drug: Third Group; Drug: Fourth Group
Sponsors: Penn State University; Penn State University
Recruiting - verified July 2011
A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Conditions: Bone Metastases; Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 chloride) + docetaxel; Drug: Docetaxel
Sponsors: Algeta ASA; Algeta ASA; Bayer
Recruiting - verified October 2011
L-Arginine Supplementation With or Without Enzyme Inhibitors In Treating Erectile Function and Quality of Life of Prostate Cancer Survivors Previously Treated With Radiation Therapy

Conditions: Cancer Survivor; Male Erectile Disorder; Prostate Cancer; Radiation Toxicity
Interventions: Dietary Supplement: L-arginine/Korean ginseng/ Gingko biloba/damiana-based supplement; Other: placebo
Sponsors: National Cancer Institute (NCI); Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified August 2011
Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up

Condition: Prostate Cancer
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified February 2012
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer
Interventions: Drug: lenalidomide; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Conditions: Prostate Cancer; Metastatic Castrate Resistant Prostate Cancer
Intervention: Drug: TRC105
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Conditions: Advanced Solid Tumors; Adenocarcinoma of the Prostate
Intervention: Drug: MLN8237 plus docetaxel
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction

Conditions: Prostate Cancer; Erectile Dysfunction
Intervention: Biological: injection of bone marrow mononucleated cells
Sponsors: Institut National de la Santé Et de la Recherche Médicale, France; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2011
Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis

Conditions: Interstitial Cystitis; Chronic Prostatitis
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified December 2011
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: LHRHa
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Recruiting - verified December 2010
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer

Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma

Conditions: Bone Cancer; Bone Metastases; Pain
Interventions: Device: Exablate treatment; Radiation: Radiation
Sponsors: InSightec; InSightec
Recruiting - verified February 2012
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Testosterone; Drug: Etoposide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified May 2012
Preoperative Magnetic Resonance (MR) Imaging of Prostate Cancer

Condition: Prostate Cancer
Intervention: Other: Preoperative MRI
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified December 2011
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System

Conditions: Bone Cancer; Bone Metastases; Pain
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified February 2012
Vitamin C as an Anti-cancer Drug

Condition: Prostatic Neoplasms
Intervention: Drug: Ascorbic Acid (Vitamin C)
Sponsors: Copenhagen University Hospital at Herlev; Copenhagen University Hospital at Herlev; Rigshospitalet, Denmark; University of Copenhagen
Recruiting - verified September 2011
Semen Analysis After Proton Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients

Condition: Intraoperative Floppy Iris Syndrome
Intervention: Procedure: anterior (more central) corneal paracentesis incision
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Hypo-fractionated radiotherapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Recurrent Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Other: questionnaire administration; Drug: cinacalcet hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy

Condition: Prostate Cancer
Intervention: Drug: sildenafil 100mg
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital; Pfizer
Recruiting - verified August 2011
Docetaxel and Sirolimus in Patients With Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Docetaxel (Taxotere); Drug: Sirolimus (Rapamycin); Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Condition: Prostate Cancer
Interventions: Drug: carboplatin; Drug: everolimus; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Conditions: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: bicalutamide; Drug: raloxifene; Procedure: quality-of-life assessment
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012
TNFerade Biologic to Treat Locally Advanced Prostate Cancer

Condition: Locally Advanced Prostate Cancer
Intervention: Biological: TNFerade™ Biologic
Sponsors: GenVec; GenVec; National Institutes of Health (NIH)
Recruiting - verified March 2012
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Interventions: Drug: LY2523355; Drug: pegfilgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
CyberKnife Radiosurgery for Localized Prostatic Carcinoma

Condition: Prostate Cancer
Interventions: Radiation: CyberKnife Radiosurgery; Radiation: CyberKnife Radiosurgery
Sponsors: CyberKnife Centers of San Diego; CyberKnife Centers of San Diego
Recruiting - verified September 2011
Proton Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Procedure: Proton Beam Radiation Therapy; Other: Quality-of-Life assessment; Other: Questionnaire Administration
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Proton Therapy , proton boost and docetaxel followed by androgen deprivation; Radiation: Conformal X-ray , proton boost and docetaxel followed by androgen deprivation
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness

Condition: Prostate Cancer
Interventions: Drug: Purified isoflavones; Drug: Methyl cellulose blend
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified January 2012
Ketoconazole and Dexamethasone in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ketoconazole, hydrocortisone; Drug: Ketoconazole, dexamethasone
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012
Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers

Conditions: Prostatic Neoplasms; Rectal Neoplasms
Intervention: Radiation: Palliative pelvic soft-tissue radiation (external beam)
Sponsors: Sorlandet Hospital HF; Sorlandet Hospital HF; Oslo University Hospital; Sykehuset Innlandet HF; Nordlandssykehuset HF; University Hospital of North Norway; Helse Stavanger HF
Recruiting - verified January 2012
Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: leuprolide acetate; Other: mass spectrometry; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Radiation: external beam radiation therapy; Drug: goserelin acetate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives

Conditions: Hereditary Prostate Cancer; Prostate Cancer
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: study of high risk factors
Sponsors: Portland VA Medical Center; Portland VA Medical Center
Recruiting - verified November 2009
Guided Biopsy for Mapping Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: Prostatectomy
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
Intervention: Drug: MCS-2
Sponsors: Health Ever Bio-Tech Co., Ltd.; Health Ever Bio-Tech Co., Ltd.
Recruiting - verified June 2011
MCS in the Treatment of Lower Urinary Tract Symptoms

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
Interventions: Drug: MCS-2 15 mg/day; Drug: MCS-2 30 mg/day; Drug: Placebo
Sponsors: Health Ever Bio-Tech Co., Ltd.; Health Ever Bio-Tech Co., Ltd.
Recruiting - verified November 2011
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
Intervention: Drug: MCS-2
Sponsors: Health Ever Bio-Tech Co., Ltd.; Health Ever Bio-Tech Co., Ltd.
Recruiting - verified June 2011
Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator

Conditions: Prostatic Neoplasms; Cancer of Prostate; Prostate Cancer; Prostate Neoplasms
Interventions: Procedure: Laparoscopic Radical Prostatectomy (without a simulator); Procedure: Laparoscopic Radical Prostatectomy (with a simulator)
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2011
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
Interventions: Drug: MCS-2; Drug: Placebo
Sponsors: Health Ever Bio-Tech Co., Ltd.; Health Ever Bio-Tech Co., Ltd.
Recruiting - verified June 2011
Pharmacokinetics of MCS in Healthy Volunteers

Condition: Healthy
Intervention: Drug: MCS-2 soft-gel capsule
Sponsors: Health Ever Bio-Tech Co., Ltd.; Health Ever Bio-Tech Co., Ltd.
Not yet recruiting - verified June 2011
Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer

Condition: Stage III Prostate Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: bone scan; Other: dual x-ray absorptometry; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer

Condition: Metastatic Prostate Cancer
Intervention:
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center
Recruiting - verified April 2012
High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer

Conditions: Prostate Cancer; Sexual Dysfunction
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified May 2011
Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer

Conditions: Breast Cancer; Prostate Cancer; Lung Cancer; Lymphoma Cancer; Gynecological Cancers
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011
Hypofractionated SBRT For Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Stereotactic Body Radiation Therapy
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified July 2011
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Condition: Bone Metastases
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Study of Prostate Samples in Predicting Cancer Recurrence in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Stereotactic Radiosurgery using the Novalis Tx
Sponsors: San Diego Radiosurgery; San Diego Radiosurgery
Recruiting - verified August 2011
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Radiation: Proton Therapy; Radiation: Photon, Proton and Hormonal Therapy; Radiation: Proton Therapy; Radiation: Photon, Proton and Hormonal Therapy
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: University of Lausanne Hospitals; University of Lausanne Hospitals; Advanced Accelerator Applications; Centre d'Imagerie Biomédicale (CIBM), Lausanne, Switzerland
Recruiting - verified April 2012
Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: S-equol; Drug: Placebo
Sponsors: Ausio Pharmaceuticals, LLC; Ausio Pharmaceuticals, LLC
Recruiting - verified September 2011
Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Recruiting - verified August 2009
Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: releasing hormone agonist therapy; Genetic: protein expression analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified August 2009
Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: vitamin D3; Drug: Placebo daily for one year
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

Conditions: Peripheral Nerve Injury; Prostate Cancer; Radical Prostatectomy; Nerve Reconstruction; Cavernous Nerve Injury
Intervention: Other: Processed Human Nerve Tissue Scaffold
Sponsors: AxoGen, Inc; AxoGen, Inc
Recruiting - verified February 2012
Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Radiation: image-guided radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy treatment planning/simulation
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified July 2009
A Study for Treatment of Superficial Bladder Cancer Using OGX-427

Condition: Bladder Cancer
Intervention: Drug: OGX-427
Sponsors: Vancouver Coastal Health; Vancouver Coastal Health; NCIC Clinical Trials Group; Vancouver General Hospital Foundation
Recruiting - verified February 2012
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Condition: Benign Prostatic Hyperplasia (BPH)
Interventions: Drug: NX-1207; Drug: Placebo
Sponsors: Nymox Corporation; Nymox Corporation
Recruiting - verified March 2012
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Condition: Metastatic Prostate Cancer
Interventions: Drug: Bevacizumab; Drug: Lenalidomide; Drug: Docetaxel; Drug: Prednisone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: SBRT Prostate
Sponsors: Duke University; Duke University
Recruiting - verified September 2011
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Prostate Cancer Prospective Cohort

Condition: Prostate Cancer
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Johns Hopkins University; National Cancer Institute (NCI); Wake Forest University
Recruiting - verified April 2012
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: leuprolide acetate; Drug: goserelin; Other: laboratory biomarker analysis; Other: quality-of-life assessment; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

Conditions: Urinary Incontinence; Prostate Cancer
Intervention: Device: Surgisis Male Sling
Sponsors: Cook; Cook
Recruiting - verified March 2012
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Condition: Hormone Refractory Prostate Cancer
Intervention: Drug: IV administration of fluorine-18 labeled methylcholine followed by PET/CT
Sponsors: Queen's Medical Centre; Queen's Medical Centre; National Cancer Institute (NCI)
Recruiting - verified November 2011
Measurement of Anti-Androgen Response Using 18F-choline PET/CT in Androgen-Insensitive Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: IV administration of fluorine-18 methylcholine followed by PET/CT imaging
Sponsors: Queen's Medical Centre; Queen's Medical Centre; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Collection of Blood From Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)

Conditions: Overactive Bladder; Benign Prostatic Hyperplasia
Intervention: Drug: doxazosin plus tolterodine SR
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified December 2011
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
A Natural History Study of Patients Receiving High-Dose Rate Brachytherapy

Conditions: Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Prostate Cancer; Biliary Cancer
Intervention: Procedure: Brachytherapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Drug: torisel
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified August 2010
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: NX-1207; Drug: Placebo
Sponsors: Nymox Corporation; Nymox Corporation
Recruiting - verified March 2012
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Conditions: Prostate Cancer; Adenocarcinoma
Intervention: Radiation: Hypofractionated, image-guided, intensity-modulated external beam radiation
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center
Recruiting - verified March 2012
Ultrasound Hyperthermia Therapy After Implant Radiation Therapy in Treating Patients With Urinary Tract Cancer, Gynecologic Cancer, or Head and Neck Cancer

Condition: Cancer
Interventions: Procedure: ultrasound hyperthermia treatment; Radiation: brachytherapy
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified May 2009
Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer

Conditions: Impotence; Prostatic Neoplasms
Interventions: Drug: Sildenafil therapy plus post-NSRRP HBO2T; Drug: Sildenafil therapy plus sham post-NSRRP HBO2T
Sponsors: Hartford Hospital; Hartford Hospital
Recruiting - verified April 2011
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: vitamin E; Procedure: sham intervention
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified December 2011
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

Condition: Prostate Cancer
Intervention: Drug: Ketoconazole
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified November 2011
Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients

Conditions: Breast Cancer; Prostate Cancer
Intervention:
Sponsors: Centre Val d'Aurelle - Paul Lamarque; Centre Val d'Aurelle - Paul Lamarque
Recruiting - verified February 2012
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

Condition: Prostate Cancer
Interventions: Drug: oral microencapsulated diindolylmethane; Other: high performance liquid chromatography; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: mass spectrometry; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation

Conditions: Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Dietary Supplement: cholecalciferol; Drug: Placebo Administration
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Conditions: Prostate Cancer; Prostatic Neoplasms
Interventions: Drug: Panobinostat (Phase II doses); Drug: Panobinostat
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis
Recruiting - verified March 2012
Prostate Conformal Cryotherapy

Condition: Prostate Cancer
Intervention: Procedure: Cryoablation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Endocare, Inc.; Gen-Probe, Incorporated; FirmaMed; Envisioneering Medical Technologies
Recruiting - verified April 2012
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011
Efficacy Study of HoLEP and TURP on LUTS Secondary to BPH

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
Interventions: Procedure: Transurethral resection of the prostate; Procedure: Holmium Laser Enucleation of the Prostate
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified December 2011
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer

Conditions: Cancer Survivor; Depression; Gastrointestinal Complications; Male Erectile Disorder; Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Urinary Complications
Interventions: Behavioral: telephone-based intervention; Other: educational intervention; Other: partner-assisted coping skills training; Other: questionnaire administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: East Carolina University; East Carolina University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Aberant Gene Expression Prostate Carcinoma

Condition: Prostate Cancer
Intervention:
Sponsors: Lahey Clinic; Lahey Clinic
Recruiting - verified June 2011
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Conditions: Prostate Cancer; Erectile Dysfunction; Urinary Toxicity
Interventions: Drug: LHRH agonist and Bicalutamide; Drug: Bicalutamide, Dutasteride and Tamoxifen
Sponsors: Centre hospitalier universitaire de Québec; Centre hospitalier universitaire de Québec; GlaxoSmithKline
Recruiting - verified February 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Registry of Hypogonadism in Men

Conditions: Male Hypogonadism; Androgen Deficiency; Testosterone Deficiency
Intervention: Other: Standard of Care
Sponsors: New England Research Institutes; New England Research Institutes; Bayer
Recruiting - verified July 2011
CyberKnife Radiosurgery for Locally Recurrent Prostate CA

Condition: Recurrent Prostate Cancer
Intervention: Radiation: CyberKnife Radiosurgery
Sponsors: CyberKnife Centers of San Diego; CyberKnife Centers of San Diego
Recruiting - verified September 2011
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1

Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified December 2011
The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing

Condition: Prostate Cancer
Intervention: Device: TRUS probe
Sponsors: Amphia Hospital; Amphia Hospital
Recruiting - verified June 2011
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

Condition: Prostate
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy

Conditions: Cancer; Fatigue
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Nursing Research (NINR)
Recruiting - verified October 2011
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: pTVG-HP with rhGM-CSF; Biological: pTVG-HP with rhGM-CSF
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI)
Recruiting - verified November 2011
Testosterone for Penile Rehab After Radical Prostatectomy

Conditions: Low Testosterone Levels; Erectile Dysfunction
Interventions: Drug: Testim® + Viagra®; Drug: Placebo Testim® + Viagra®
Sponsors: Baylor College of Medicine; Mohit Khera
Recruiting - verified December 2011
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer

Conditions: Cancer of the Prostate; Prostate Cancer; Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011
The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate

Condition: Prostate Cancer
Interventions: Device: Goldlock; Device: Visicoil smallest size; Device: Visicoil larger size; Device: Bard goldmarker smallest size; Device: Bard goldmarker larger size
Sponsors: University Hospital, Ghent; University Hospital, Ghent; IBA, Germany; Hospimed, Netherland; C. R. Bard
Recruiting - verified May 2012
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Proton Radiation; Radiation: Proton
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified May 2012
TKI258 in Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: TK1258
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2012
A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment

Condition: Prostate Cancer
Intervention:
Sponsors: Barwon Health; Barwon Health
Recruiting - verified August 2011
Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients

Condition: Prostate Cancer
Interventions: Other: Information Gathering; Other: Decision Aid
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Exercise for Prostate Cancer Patients

Condition: Prostate Cancer Related Fatigue
Intervention: Behavioral: Exercise
Sponsors: University of Rochester; University of Rochester; Department of Defense
Recruiting - verified November 2011
Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: ExAblate MRgFUS for prostate cancer
Sponsors: InSightec; InSightec
Recruiting - verified February 2012
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Condition: Prostate Cancer
Intervention: Radiation: hypofractionation
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012
Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Condition: Cancer
Interventions: Drug: hydroxychloroquine; Drug: sunitinib malate
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011
Cancer Support Programs

Condition: Prostate Cancer
Interventions: Behavioral: Group Meetings; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Prostate Cancer - Qatar

Condition: Prostate Cancer
Intervention:
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

Condition: Prostate Cancer
Interventions: Biological: Ad5-CMV-NIS; Drug: liothyronine sodium; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Radiation: iodine I 131
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy; Drug: bicalutamide; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Cancer Institute of New Jersey
Recruiting - verified February 2012
Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

Conditions: Prostate Cancer; Elevated Prostate Specific Antigen (PSA)
Intervention: Other: serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); New York Presbyterian Hospital; Weill Medical College of Cornell University; State University of New York - Downstate Medical Center; New York University School of Medicine; Kings County Hospital
Recruiting - verified January 2012
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism

Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism
Interventions: Device: Comprehensive computed tomography of the abdomen/pelvis; Other: Limited Malignancy Screening
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Recruiting - verified October 2011
Magnetic Resonance (MR) Spectroscopy in Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Procedure: 3T MR Spectroscopy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Prostate Active Surveillance Study

Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified June 2011
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: selenomethionine; Drug: finasteride; Other: placebo
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified May 2012
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: hydroxychloroquine
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified March 2012
Natural Killer Cells and Bortezomib to Treat Cancer

Conditions: Lung or Prostatic Neoplasms; Colorectal or Kidney Neoplasms; Pancreatic Neoplasms; Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive; Melanoma; CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Condition: Prostate Cancer
Intervention: Biological: peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia

Condition: Benign Prostatic Hyperplasia
Interventions: Drug: selective alpha 1-blockers; Drug: celecoxib; Drug: alpha-blocker and NSAID
Sponsors: Samsung Medical Center; Samsung Medical Center; The Korean Urological Association
Recruiting - verified December 2011
Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Conditions: Cancer; Solid Tumor
Intervention: Drug: CALAA-01
Sponsors: Calando Pharmaceuticals; Calando Pharmaceuticals
Recruiting - verified February 2012
Green Tea or Water in Treating Patients With Prostate Cancer Undergoing Surgery

Condition: Prostate Cancer
Interventions: Dietary Supplement: green tea; Dietary Supplement: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)

Condition: Metastatic Castration Resistant Prostate Cancer (CRPC)
Intervention: Drug: Hamsa-1™ TL-118
Sponsors: Tiltan Pharma Ltd.; Tiltan Pharma Ltd.
Recruiting - verified August 2011
Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers

Condition: Prostate Cancer
Interventions: Procedure: 3T MR Imaging; Procedure: C-Choline PET Scanning; Procedure: Gene Rearrangement
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012
Metabolic Effects of Androgenicity in Aging Men and Women

Conditions: Aging; Insulin Resistance
Interventions: Drug: Testosterone; Drug: Estrogen
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012
Herbal Therapy for Treatment of Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention: Dietary Supplement: Prostate Health Cocktail
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified November 2011
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Placebo
Sponsors: NorthShore University HealthSystem Research Institute; NorthShore University HealthSystem Research Institute; University of Chicago; Northwestern University
Recruiting - verified April 2008
Linkage Analysis in Interstitial Cystitis

Conditions: Prostatitis; Cystitis, Interstitial; Urinary Bladder, Overactive; Chronic Pelvic Pain Syndrome; Painful Bladder Syndrome
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center
Recruiting - verified January 2012
Diagnostic Challenges in IC (and Male CPPS)

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome; Chronic Bacterial Prostatitis; Asymptomatic Inflammatory Prostatitis; Painful Bladder Syndrome; Cystitis, Interstitial
Intervention: Genetic: Genomic and proteomic biomarker discovery
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified June 2011
The Physical Exercise and Prostate Cancer Study

Condition: Prostate Cancer
Interventions: Behavioral: Experimental A: Strength training; Other: No Intervention
Sponsors: Oslo University Hospital; Oslo University Hospital; Ullevaal University Hospital; Norwegian School of Sport Sciences; University of Alberta, Physical Education; University of Oslo; Norwegian Foundation for Health and Rehabilitation; The Royal Norwegian Ministry of Health
Recruiting - verified July 2011
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Condition: Prostate Cancer
Intervention: Drug: Revlimid
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.; Celgene Corporation
Recruiting - verified August 2010
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

Conditions: Localized Breast Cancer; Localized Prostate Cancer; Patients Receiving External Beam Radiotherapy
Interventions: Dietary Supplement: Organic Germanium; Dietary Supplement: Placebo
Sponsors: Arizona Oncology Services; Arizona Oncology Services
Recruiting - verified June 2011
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: paricalcitol; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2010
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers

Conditions: Melanoma; Breast Cancer; Prostate Cancer
Intervention: Drug: CVA21
Sponsors: Viralytics; Viralytics
Recruiting - verified October 2011
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer

Condition: Solid Tumors
Intervention: Biological: MT110
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified January 2012
A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer

Condition: Prostate Cancer
Intervention: Biological: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine
Sponsors: Biotech Equity Partners Pty Ltd; Biotech Equity Partners Pty Ltd
Recruiting - verified July 2011
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

Conditions: Hematuria; Hematospermia
Intervention: Drug: Finasteride
Sponsors: University of British Columbia; University of British Columbia; Health Canada; Merck Frosst Canada Ltd.
Recruiting - verified April 2012
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia

Condition: Prostatic Hyperplasia
Interventions: Drug: Polyphenon E; Drug: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla

Conditions: Prostate Cancer; MRI
Intervention: Other: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men

Condition: Prostate Cancer
Intervention: Behavioral: questionnaires of quality of life
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University School of Medicine(VA-NYU); State University of New York - Downstate Medical Center; Kings County Hospital Center
Recruiting - verified December 2011
Men Undergoing Radical Prostatectomy

Condition: Prostate Cancer
Intervention: Other: Whole Blood Draw
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012
Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Behavioral: Interview; Behavioral: survey instruments using Web-Based Data Collection System (WBDC) survey content
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

Condition: Hormone Refractory Prostate Cancer
Intervention: Biological: ADENOVIRUS/PSA VACCINE
Sponsors: University of Iowa; University of Iowa; Department of Defense
Recruiting - verified March 2012
Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

Condition: Recurrent Prostate Cancer
Intervention: Biological: Adenovirus/PSA Vaccine
Sponsors: University of Iowa; University of Iowa; Department of Defense
Recruiting - verified March 2012
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Conditions: Breast Cancer; Colon Cancer; Prostate Cancer
Intervention: Genetic: PCR/PCR/LDR Strategy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; Weill Medical College of Cornell University
Recruiting - verified November 2011
Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

Condition: Prostate Cancer
Intervention: Drug: lovastatin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; Hunter Holmes Mcguire Veteran Affairs Medical Center
Recruiting - verified April 2012
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Condition: Prostate Cancer
Interventions: Behavioral: Questionaires; Behavioral: Questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); City of Hope National Medical Center; Fordham University; Columbia University; New York University Medical Center
Recruiting - verified March 2012
Molecular Studies and Clinical Correlations in Human Prostatic Disease

Condition: Prostate Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Rockefeller University; Flinders Medical Centre; Aureon Biosciences, Inc.; University of Southern California; Gen-Probe, Incorporated; Genentech; General Electric; Purdue University; Biocept, Inc.; Duke University; Ikonysis, New Haven, CT; Array Genomics; Cold Spring Harbor Laboratory
Recruiting - verified December 2011
Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy

Conditions: Prostate Cancer; Quality of Life
Intervention: Behavioral: Quality of Life Questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The Cleveland Clinic
Recruiting - verified December 2011
Spectroscopy With Surface Coils and Decoupling

Conditions: Adrenal Cortical Cancer; Brain Cancer; Breast Cancer; CNS Cancer; Colon Cancer; HEENT Cancer; Hodgkin's Disease; Kaposi's Sarcoma; Liver Cancer; Lung Cancer; Non-Hodgkin's Lymphoma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Sarcoma; Squamous Cell Carcinoma; Thyroid Cancer
Interventions: Device: Proton-decoupled 31P MRS at 1.5T; Device: 1H Spectroscopy at 1.5T and 3T
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University; University of Pennsylvania; St.George's Hospital (England); Royal Marsden NHS Foundation Trust; University Medical Center Nijmegen; Weill Medical College of Cornell University
Recruiting - verified February 2012
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

Conditions: Breast Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Leukemia; Lymphoma, Non-Hodgkin
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified May 2012
Statin Therapy Versus Placebo Prior to Prostatectomy

Conditions: Cancer; Prostate
Interventions: Drug: Simvastatin; Other: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Oregon Health and Science University
Recruiting - verified May 2012
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
FACBC PET/CT for Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: [18F]FACBC
Sponsors: Emory University; David M. Schuster, MD
Recruiting - verified December 2011
Quality of Life Study for Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)

Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009
Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: calcitriol; Drug: ketoconazole; Drug: therapeutic hydrocortisone
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified January 2012
Brachytherapy for Prostatic Carcinoma Patients

Condition: Prostate Cancer
Interventions: Procedure: Brachytherapy; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients Previously Treated With Docetaxel

Conditions: Prostate Cancer; Pain
Interventions: Drug: Azacitidine; Drug: Docetaxel; Drug: Prednisone; Genetic: Azacitidine induced demethylation of repetitive elements.; Genetic: GADD45α methylation and expression in prostate cancer tissue; Genetic: GADD45α methylation in serum DNA
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
Multicentric Study Comparing Carcinological and Functional Results of Surgery

Condition: Cancer of the PROSTATE
Interventions: Procedure: Radical retropubic prostatectomy; Procedure: Radical laparoscopy prostatectomy
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified January 2008
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: cholecalciferol; Dietary Supplement: genistein; Dietary Supplement: soy isoflavones; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Conditions: Chronic Prostatitis (CP); Chronic Pelvic Pain Syndrome (CPPS); Painful Bladder Syndrome (PBS); Benign Frequency Syndrome (BFS); Benign Daytime Frequency Syndrome (BDFS)
Intervention:
Sponsors: Children's Hospital Boston; Children's Hospital Boston; National Institutes of Health (NIH)
Recruiting - verified July 2011
Active Surveillance in Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Study of Quality of Life for Prostate Proton Therapy

Condition: Prostate Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Effect of Weight Loss on Prostate Cancer Pathology

Conditions: Obesity; Prostate Cancer
Interventions: Behavioral: Weight Loss; Other: No Weight Loss Group
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified February 2012
3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

Condition: Prostate Cancer
Intervention: Procedure: 3T Magnetic Resonance Spectroscopic Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified December 2011
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Flutamide; Biological: Sargramostim; Biological: recombinant fowlpox-prostate apecific antigen vaccine; Biological: recombinant vaccinia prostate specific antigen vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Samarium Sm 153 lexidronam pentasodium; Biological: Sargramostim; Biological: Recombinant vaccinia-TRICOM vaccine; Biological: Recombinant fowlpox-TRICOM vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: type of decision aid
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified November 2011
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate

Condition: Prostate Cancer
Interventions: Procedure: AIR-MRSI; Procedure: PFC-MRSI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Condition: Prostate Cancer
Intervention: Drug: Gleevec + Sorafenib
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.
Recruiting - verified August 2010
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Sorafenib
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.
Recruiting - verified August 2010
PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prolieve® Thermodilatation System
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified June 2011
Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: physiologic testing; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified October 2006
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
Quality of Life Following Radical Prostatectomy

Conditions: Prostatic Neoplasms; Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Survey of Prostate Cancer in Accra, Ghana

Condition: Prostate Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified December 2011
An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males

Condition: Prostate Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Conditions: Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer
Interventions: Drug: releasing hormone agonist therapy; Drug: transdermal estrogen
Sponsors: National Cancer Institute (NCI); Imperial College London
Recruiting - verified June 2008
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: hybrid PET-CT imaging system
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer

Condition: Intraabdominal Cancers (Various Types)
Intervention: Biological: Implantation of cancer macrobeads in the abdominal cavity by laparoscopy
Sponsors: The Rogosin Institute; The Rogosin Institute
Recruiting - verified April 2012
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

Condition: Prostate Cancer
Interventions: Drug: celecoxib; Drug: docetaxel; Drug: prednisolone; Drug: releasing hormone agonist therapy; Drug: zoledronic acid; Drug: abiraterone; Procedure: orchiectomy
Sponsors: Medical Research Council; Medical Research Council
Recruiting - verified March 2012
Microarray Analysis of Gene Expression in Prostate Tissues

Condition: Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy

Condition: Prostate Cancer
Interventions: Procedure: Androgen suppression, radiotherapy; Procedure: Androgen suppression, radiotherapy, iodine 125 brachytherapy
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012
Laser Prostatectomy Database and Registry

Conditions: Benign Prostatic Hyperplasia; Enlarged Prostate
Intervention: Other: Registry and Database
Sponsors: Indiana Kidney Stone Institute; Indiana Kidney Stone Institute
Recruiting - verified April 2012
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Conditions: Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Biological: OGX-011
Sponsors: University of British Columbia; University of British Columbia; Department of Defense
Recruiting - verified April 2012
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Androgen Hormonal Suppression and Radiation; Drug: Androgen Suppression Therapy and Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Sanofi-Aventis
Recruiting - verified June 2011
Dutasteride to Treat Women With Menstrually Related Mood Disorders

Conditions: Premenstrual Syndrome; PMS; Healthy; Depression
Interventions: Drug: Dutasteride; Drug: Placebo oral capsule
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified April 2012
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Conditions: Leiomyomatosis; Kidney Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified April 2009